Biogen isn’t wasting any time integrating its multibillion-dollar purchase of Apellis, revealing plans to part ways with some of the biotech’s staffers and halt work on most of its research programs.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Biogen isn’t wasting any time integrating its multibillion-dollar purchase of Apellis, revealing plans to part ways with some of the biotech’s staffers and halt work on most of its research programs.